GlassScriptPhysician profile
James Hoppers
NPI 1376511212
$752.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.47 · 2020: $145 · 2021: $167 · 2022: $259 · 2023: $108 · 2024: $16.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.69 | 2020-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $119.38 | 2022-2023 | |
| Lilly USA, LLC | $96.34 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.62 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $66.32 | 2020-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.05 | 2020-2023 | Xifaxan |
| Genentech USA, INC. | $44.35 | 2019 | |
| Sanofi Pasteur INC. | $25.29 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $21.13 | 2021 | |
| Esperion Therapeutics, INC. | $17.69 | 2021 | |
| Scynexis, INC. | $17.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.52 | 2022 | |
| Eisai INC. | $16.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hoppers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.